CRS Robotics Corporation and Millipore to Co-Market Optimal Sample Prep for the Ultra-High Throughput Assay Market.

Business Editors & Health/Medical Writers

BIOWIRE2K

BURLINGTON, Ontario & BEDFORD, Mass.--(BW HealthWire)-- Jan. 22, 2002

CRS Robotics Corporation (TSE:ROB.) and Millipore Corporation (NYSE:MIL) today announced a non-exclusive agreement to co-market automated, ultra-high throughput sample-prep applications for genomics, proteomics and drug discovery. These solutions combine CRS instrumentation with Millipore's sample-prep platforms and validated software protocols.

Ralph Steedman, President & CEO of CRS said, "By combining our instrumentation with Millipore technology, we can provide automated sample preparation solutions for some of the world's highest throughput research centers. To our knowledge this is the first ultra high throughput system available to the market for this application. Our mission is to pioneer advanced sample-prep methods by equipping our customers with robust systems and optimized protocols."

"Millipore continues to identify partners whose capabilities are a natural extension of our own," said Bill Emhiser, President of Millipore's Life Science Division. "Developed for use on robotic systems, our sample-prep technology is ideally suited to meet the demands of CRS' high throughput customers."

The agreement further establishes both companies' competitive position in the sample-prep purification market for Life Science customers. Millipore's high throughput sample-prep platforms include 96- and 384-well Montage kits for genomics sample prep applications including PCR cleanup, sequencing reaction cleanup, BAC minipreps and plasmid minipreps.

About CRS

Core competencies for CRS include integrated lab automation solutions using advanced software in biotechnology and pharmaceutical research applications marketed worldwide. In addition, CRS manufactures and supplies robotic systems for advanced manufacturing niche markets. CRS is headquartered in Burlington, Ontario and has subsidiaries in the United States and Europe. Further information can be found on the company's web site at www.crsrobotics.com.

About Millipore

Millipore is a multinational, high technology bioscience company that provides technologies, tools and services for the development and production of new therapeutic drugs. It serves the life science research, biotechnology and pharmaceutical industries. For more information visit www.millipore.com.

CRS Forward Looking Statement Disclaimer

Some of the matters discussed in this news release involve risks and uncertainties, which include, but are not limited to, risks and uncertainties regarding the Company's ability to generate high growth sales rates and uncertainties related to economic conditions, markets, products, competition, intellectual property, services and prices, key employees and future capital needs that the company depends on. Additional information on these and other potential factors that could affect the Company's financial results are detailed in documents filed from time to time with the Ontario Securities Commission. The Company undertakes no responsibility to update forward-looking statements if circumstances or management's projections, beliefs or opinions change.

Millipore Forward Looking Statement Disclaimer

The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, difficulties in the successful separation of the biosciences and microelectronics businesses; difficulties in the successful implementation of our restructuring activities; foreign exchange rates; increased regulatory concerns on the part of the biopharmaceutical industry; further consolidation of drug manufacturers; competitive factors such as new membrane technology; availability of raw materials or component products on a timely basis; inventory risks due to shifts in market demand; change in product mix; conditions in the economy in general; potential environmental liabilities; the inability to utilize technology in current or planned products due to overriding rights by third parties; difficulties inherent in research and development activities; and the risk factors listed from time to time in Millipore's filings with the SEC.